131 related articles for article (PubMed ID: 25536605)
1. Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer.
Uysal M; Ozdogan M; Kargi A; Gunduz S; Sezgin Goksu S; Murat Tatli A; Arslan D; Mutlu H; Senol Coskun H; Bozcuk H
J BUON; 2014; 19(4):980-4. PubMed ID: 25536605
[TBL] [Abstract][Full Text] [Related]
2. Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study.
Harsh KK; Jakhar SL; Maheshwari G; Nirban R; Kumari P; Beniwal SK; Sharma N; Kumar HS
Indian J Cancer; 2023; 60(2):167-172. PubMed ID: 37530237
[TBL] [Abstract][Full Text] [Related]
3. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
[TBL] [Abstract][Full Text] [Related]
6. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
El-Husseiny K; Motawei H; Ali MS
Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
8. Oral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient.
Villa M; Attianese D; Petracchini M; Ferrero A
Anticancer Drugs; 2019 Oct; 30(9):964-968. PubMed ID: 31305269
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
10. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
Yan X; An N; Jiang GQ; Gao M; Gao YN
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan RJ; Doroshow JH; Leong L; Schriber J; Shibata S; Forman S; Hamasaki V; Margolin K; Somlo G; Alvarnas J; McNamara M; Longmate J; Raschko J; Chow W; Vasilev S; McGonigle K; Yen Y
Bone Marrow Transplant; 2001 Nov; 28(9):859-63. PubMed ID: 11781646
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
13. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
Matulonis UA; Pereira L; Liu J; Lee H; Lee J; Whalen C; Campos S; Atkinson T; Hill M; Berlin S
Gynecol Oncol; 2012 Jul; 126(1):41-6. PubMed ID: 22487536
[TBL] [Abstract][Full Text] [Related]
14. A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.
Gebbia V; Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scollo P
J Oncol Pharm Pract; 2024 Jul; 30(5):853-859. PubMed ID: 37501558
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
16. Oral etoposide for refractory or recurrent epithelial ovarian cancer.
Thavaramara T; Tangjitgamol S; Manusirivithaya S; Leelahakorn S
J Med Assoc Thai; 2009 Nov; 92(11):1397-405. PubMed ID: 19938729
[TBL] [Abstract][Full Text] [Related]
17. A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine.
Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scibilia G; Scollo P; Gebbia V
J Oncol Pharm Pract; 2024 Jan; 30(1):173-181. PubMed ID: 38018146
[TBL] [Abstract][Full Text] [Related]
18. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.
Ferrandina G; Corrado G; Mascilini F; Malaguti P; Samaritani R; Distefano M; Masciullo V; Di Legge A; Savarese A; Scambia G
BMC Cancer; 2014 Dec; 14():947. PubMed ID: 25495785
[TBL] [Abstract][Full Text] [Related]
19. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
Aigner J; Bischofs E; Hallscheidt P; Sohn C; Schneeweiss A; Eichbaum M
Anticancer Drugs; 2011 Nov; 22(10):1030-3. PubMed ID: 21970854
[TBL] [Abstract][Full Text] [Related]
20. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
